DEM BioPharma

DEM Bio welcomes Wendy Young to its Scientific Advisory Board: bit.ly/3Ns5Fhq

DEM Bio is thrilled to welcome Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board: bwnews.pr/3ZNicj1

We're honored to jump down the rabbit hole of the innovation ecosystem as a @NewEnglandVC #NEVYs22 nominee for the Life Science Emerging Company of the Year. Learn more about our mission to target “don’t eat me” signals between cancer cells & macrophages: dembiopharma.com

Following our successful launch with a $70M financing in June, we welcome Nenad Grmusa as CEO, Christophe Quéva, Ph.D., as CSO & Loise Francisco-Anderson, Ph.D., as SVP & Head of Biology as we continue to pioneer the next generation of immunotherapeutics: bwnews.pr/3RgHz7O

#ICYMI We launched with a $70M financing! We're focused on accessing the untapped opportunity around macrophage biology and innate immune system pathways to discover potent DEM and EM signals on cancers and expand the therapeutic potential of the field. bwnews.pr/3xKQlDy

We're excited to announce our launch with a $70M financing! Leveraging a proprietary CRISPR screening platform and macrophage biology, we are systematically discovering and targeting novel “don’t eat me” (DEM) and “eat me” (EM) signals to eliminate cancer. bwnews.pr/3xKQlDy